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Abstract
Parkinson’s disease is a chronic neurodegenerative disease characterized by a significant
loss of dopaminergic neurons within the substantia nigra pars compacta region and a subse-
quent loss of dopamine within the striatum. A promising avenue of research has been the
administration of growth factors to promote the survival of remaining midbrain neurons,
although the mechanism by which they provide neuroprotection is not understood. Activin A,
a member of the transforming growth factor β superfamily, has been shown to be a potent
anti-inflammatory following acute brain injury and has been demonstrated to play a role in
the neuroprotection of midbrain neurons against MPP+-induced degeneration in vitro. We
hypothesized that activin A may offer similar anti-inflammatory and neuroprotective effects
in in vivo mouse models of Parkinson’s disease. We found that activin A significantly attenu-
ated the inflammatory response induced by both MPTP and intranigral administration of lipo-
polysaccharide in C57BL/6 mice. We found that administration of activin A promoted
survival of dopaminergic and total neuron populations in the pars compacta region both 8
days and 8 weeks after MPTP-induced degeneration. Surprisingly, no corresponding pro-
tection of striatal dopamine levels was found. Furthermore, activin A failed to protect against
loss of striatal dopamine transporter expression in the striatum, suggesting the neuroprotec-
tive action of activin A may be localized to the substantia nigra. Together, these results pro-
vide the first evidence that activin A exerts potent neuroprotection and anti-inflammatory
effects in the MPTP and lipopolysaccharide mouse models of Parkinson’s disease.
Introduction
Parkinson’s disease (PD) is a chronic neurodegenerative disease characterized by significant
loss of dopaminergic neurons within the substantia nigra pars compacta (SNpc) and a
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subsequent loss of dopamine (DA) within the striatum. While the use of levodopa remains the
gold standard in the treatment of the motor symptoms, this therapeutic strategy does not
address the underlying nigral degeneration. Considerable research has therefore been directed
at aiming to identify therapeutic treatments that are able to overcome this issue. One of the
most promising avenues in recent years has been the administration of growth factors to pro-
mote the survival of remaining midbrain neurons, however the mechanism by which they pro-
vide neuroprotection has yet to be fully understood.
Growth factors have long been known to be critical in the induction, specification, survival
and maturation of developing neurons within the CNS. Following injury, growth factors and
their receptors have been shown to increase in concentration, suggesting they are part of an
endogenous mechanism aimed at an attempted regenerative response [1]. While their exact
mechanisms of action still remain to be fully elucidated, growth factors have been demon-
strated to act as neuroprotective molecules against cytotoxic cell damage via upregulation of
calcium buffering proteins, antioxidant enzymes, and anti-apoptotic factors [2].
Activin A is a member of the transforming growth factor (TGF)-β superfamily, which is
known to be involved in development, repair of tissues and organs, and in neuroinflammation.
In addition to its known neuroprotective effects in the hippocampus [3], activin A has been
shown to exert neuroprotective effects in midbrain neurons in vitro, with dopaminergic neuro-
nal cultures that have been treated with activin A maintaining a higher number of tyrosine
hydroxylase (TH) positive neurons 8 days after culture compared to untreated controls, repre-
senting a 2.5 fold increase in the survival of dopaminergic neurons [4]. Furthermore, when
administered prior to exposure with the parkinsonian neurotoxin MPP+, activin A treatment
resulted in an approximate 50% survival rate of dopaminergic neurons [4]. In addition, exoge-
nous application and transfection with activin A significantly increased human SHSY5Y neu-
roblastoma cell viability following serum withdrawal and 6-OHDA administration, with this
neuroprotection inhibited by the activin-binding protein follistatin [5].
More recently activin A was shown to provide significant neuroprotection of midbrain neu-
ron populations in vivo, with exogenous activin A significantly attenuating degeneration
induced by unilateral 6-OHDA lesioning [6]. While these results suggest that activin A may
also protect against other parkinsonian toxins in vivo, the mechanism by which this growth
factor exerts its neuroprotection remains to be found.
Neuroinflammation has steadily been gaining prominence as a significant factor in the
pathogenesis of PD [7–11]. While there have been studies demonstrating the effect of growth
factors on the inflammatory response in both the healthy and PD brain [12–15], a study con-
ducted by Abdipranoto-Cowley et al., (2009) provided the first evidence for a potent anti-
inflammatory effect of activin A in the brain after acute degeneration. Following intracerebro-
ventricular (i.c.v) injection of kainic acid and a subsequent inflammatory response, the admin-
istration of exogenous activin A was able to exert its anti-inflammatory effects in the CNS by
suppressing microglial numbers, microglial activation, pro-inflammatory cytokine release, and
gliosis both in vivo and in vitro [16]. This centrally derived anti-inflammatory process was sig-
nificantly attenuated by the administration of follistatin, with animals receiving follistatin dis-
playing increased microglial numbers and gliosis and at levels significantly higher than those
induced by kainic acid alone. Furthermore, activin A was able to profoundly limit the response
induced by the direct inflammatory stimulator lipopolysaccharide (LPS) [16]. This study is the
first to provide evidence that exogenous application of activin A prior to 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) administration provides significant protection of midbrain
neurons from degeneration in vivo and furthermore provides evidence that its neuroprotective
actions may derive from its potent anti-inflammatory properties.
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C57BL/6 male mice aged 11 weeks were obtained from Australian BioResources (Moss Vale,
Australia). Mice were housed at a maximum five mice per cage for 1 week, until the study
began, at which time mice were housed individually. Mice were kept on a 12-hour light/dark
cycle and access to food and water ad libitum. All animal procedures were performed with the
approval of the Garvan Institute and St. Vincent’s Hospital Animal Ethics Committee under
approval numbers 09/14 and 12/36, in accordance with the Australian National Health and
Medical Research Council animal experimentation guideline and the local Code of Practice for
the Care and Use of Animals for Scientific Purposes (2004). All surgery was performed under
ketamine/xylazil anesthesia, and all efforts were made to minimize suffering.
MPTP administration
Animals received subcutaneous injections of 20 mg/kg of MPTP (Sigma Aldrich) as described
in detail previously [6]. All mice were sacrificed either 8 days or 8 weeks after the final admin-
istration of MPTP or saline.
Intranigral injection of lipopolysaccharide
Mice were anaesthetized with a mixture of ketamine (8.7 mg/ml; Mavlab) and xylazil (2 mg/ml;
Troy Laboratories Pty Ltd) and placed in a stereotaxic apparatus (Kopf Instruments). Mice
were then injected with 2 μl of 5 μg/μl of LPS, or vehicle control, at a rate of 0.5 μl/minute in
the substantia nigra at the following coordinates relative to bregma: AP -3.0, ML +1.3, DV -4.7.
All mice were sacrificed 15 days after lesioning.
Osmotic micropump implantation
The day prior to MPTP, or the day after LPS administration, animals were anaesthetized and
placed in a stereotaxic apparatus as described above. For all MPTP experiments, osmotic
micro-pumps (Model 1007D; Alzet) were filled with 24.5 ng/μl (295 ng total daily dose) of
recombinant human/mouse/rat activin A (R&D Systems) or vehicle control (1x PBS) and
implanted subcutaneously along the back of the neck. For all LPS experiments osmotic micro-
pumps (Model 1002D; Alzet) were filled with 49 ng/μl (295 ng total daily dose, corresponding
to dose used in MPTP experiments) of activin A or vehicle control. An infusion cannula (Plas-
ticsOne) connected to the micropump was placed in the right lateral ventricle at AP -0.26,
ML +1.0, DV -2.8 relative to bregma. For all long-term MPTP studies the pump was removed
1 week later and the cannula tubing sealed with heat.
Immunohistochemistry
Mice were anaesthetized and transcardially perfused with ice-cold phosphate-buffered saline
(PBS) and 4% paraformaldehyde. Brains were harvested and processed as described in detail
previously [6]. Sections were incubated in the following primary antibodies: monoclonal mouse
tyrosine hydroxylase (TH, 1:1000 Sigma Aldrich cat # T2928), monoclonal mouse neuronal
nuclei (NeuN 1:500, Merck Millipore, cat # MAB377), polyclonal rabbit glial fibrillary acidic
protein (GFAP 1:300, Dako cat # Z033401), polyclonal rabbit Iba1 (1:1000, Novachem, cat #
019–19741) for 72 hours at 4˚C. All sections were then incubated in the respective biotin-labeled
secondary antibodies (1:250, Sapphire Bioscience cat # AB6813, Life Technologies, cat # B-2770)
overnight at 4˚C followed by incubation in avidin-biotin complex (Vector Laboratories) at
room temperature for 1 hour. TH immunolabeling was detected with 3,3’-Diaminobenzidine
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(DAB, Abacus) until desired staining achieved. NeuN, GFAP and Iba1 immunolabeling was
detected with DAB intensified with nickel ammonium sulfate and counterstained with poly-
clonal rabbit anti-TH (1:1000, Merck Millipore cat # AB152) that was detected with Nova-Red
(Abacus) to outline the substantia nigra region.
Stereology
Quantification of SNpc cell population estimates was performed using the optical fractionator
method and the use of Stereo Investigator 7 software (MBF Bioscience). For the estimations of
TH positive populations a counting frame of 60 μm x 60 μm and a grid size of 113 μm x 73 μm
was used. For the estimations of NeuN positive populations a counting frame of 65 μm x
65 μm and a grid size of 155 μm and 125 μm was used. For the estimation of GFAP and Iba1
positive populations a counting frame of 58 μm x 58 μm and a grid size of 61 μm x 61 μm was
used. For all cell types the guard zone height used was 5 μm and dissector height used was
10 μm with every third section sampled to a total of 10 sections for TH and NeuN quantifica-
tion, and every sixth section sampled to a total of 5 sections for GFAP and Iba1 quantification.
Coefficient of error attributable to the sampling was calculated according to Gundersen and
Jensen [17]. Errors0.10 were regarded as acceptable. The SNpc was delineated from -2.8 to
-3.88 mm relative to bregma based on the Paxinos atlas for the mouse brain [18].
Catecholamine analysis
Animals were sacrificed by cervical dislocation either 8 days or 8 weeks after the administra-
tion of MPTP or saline, the brains removed and the striatum rapidly dissected out and snap
frozen. Striata were analysed for norepinephrine (NE), dopamine (DA), 3,4-dihydroxypheny-
lacetic acid (DOPAC), and homovanillic acid (HVA) via HPLC as described previously [6].
Catecholamine levels were standardized to protein levels measured via Bradford assay and
recorded as ng/μg of protein. All standards for the Bradford assay were prepared in freshly
made 0.2 M PCA + 0.1% L-cysteine.
Western blotting
Animals were sacrificed by cervical dislocation either 8 days or 8 weeks after the administra-
tion of MPTP or saline or 15 days after the administration of LPS, the brains removed and the
striatum rapidly dissected out and snap frozen. Striata were sonicated in protease inhibitor
cocktail (Sigma) diluted at a concentration of 1:1000 in RIPA buffer (Sigma) and centrifuged
at 16,000g for 15 minutes at 4˚C. For all samples, 10 μg was loaded onto 4–12% Bis-Tris gels
(Life Technologies) and protein was separated by running the gel at 180V for approximately
45 minutes. Following transfer to PDVF membranes (Life Technologies), membranes were
blocked in 10% skim milk solution for 1 hour at room temperature and then incubated in
0.1% BSA solution containing either polyclonal rabbit phosphorylated TH(Ser40) (Thermo
Fischer Scientific cat # sc-135715), polyclonal rabbit phosphorylated TH(Ser31) (Thermo
Fischer Scientific cat # sc-135714) or monoclonal rat dopamine transporter (DAT) antibody
(Merck Millipore cat # MAB369) at a concentration of 1:1000 and kept at 4˚C overnight on an
orbital shaker. Following washing in buffer containing 1 x TBS buffer without triton + 0.1%
Tween 20 for 1 hour, membranes were incubated in 5% skim milk solution containing the
respective HRP secondary antibodies (1:1000, Sapphire Bioscience cat # AB97057 and Merck
Millipore cat # AP132P) for 1 hour at room temperature. Membranes were then visualized
using Novex ECL Chemiluminescent Substrate Reagent Kit (Life Technologies) and exposed
to x-ray film (FUJIFILM). Films were scanned and analyzed using Image J Software.
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All membranes probed for p-TH(Ser40) and p-TH(Ser31) were then stripped and re-
probed with monoclonal mouse anti-TH (1:1000 Sigma Aldrich, cat # T2928) followed by
stripping and re-probing with monoclonal rabbit anti-GAPDH (1:1000, Cell Signaling cat #
2118). All membranes probed for DAT were stripped and re-probed for anti-GAPDH. Films
were scanned and analyzed using Image J Software. For quantification of all phosphorylation
western blots, the raw values were first expressed as a ratio to total TH, standardized to
GAPDH and then adjusted with the values obtained from PBS + Saline treated mice. For quan-
tification of DAT western blots, raw values were standardized to GAPDH and adjusted with
the values obtained from PBS + Saline treated mice.
Activin ELISA
Mice were sacrificed by cervical dislocation and the striatum and midbrain (substantia nigra +
ventral tegmental area) rapidly dissected out 24 hours after the last MPTP (or saline) injection.
Tissues were homogenized in lysis buffer containing 5 mM Tris-HCL, pH 8.0, 0.32 M sucrose,
and protease inhibitor cocktail (Sigma Aldrich, Australia), and homogenates were centrifuged
at 17,000xg at 4˚C for 10 minutes. Supernatant was collected and assayed for quantification of
total protein via Bradford assay. Activin A levels were assayed by ELISA kit (Quantikine Acti-
vin A assay, R&D systems) according to manufacturer’s instructions.
Statistical analysis
All statistical analysis was performed using GraphPad Prism Version 6.0 (GraphPad Software,
Inc). Differences between means was assessed, as appropriate, by two- or one-way ANOVA
followed by Bonferroni post hoc analysis, or via unpaired t test or Mann-Whitney testing.
Results
Activin A increases survival of dopaminergic neurons in the substantia
nigra following MPTP
It has been previously shown that activin A is able to protect against MPP+-induced degener-
ation in vitro [4]. To investigate if exogenous application of activin A exerts the same neuro-
protective effects in vivo, surviving midbrain dopaminergic neurons, identified by TH
immunoreactivity, were quantified in the SNpc region via stereology. As expected, MPTP
administration resulted in a significant loss of TH positive neurons (Interaction F(1,16) =
3.118 p = 0.0965; Toxin F(1,16) = 16.62 p<0.001; Drug F(1,16) = 15.66 p<0.01, n = 5/group)
with animals receiving PBS displaying significantly fewer TH positive cells following MPTP
compared to their saline controls (p<0.01). However, i.c.v infusion of activin A significantly
increased the number of surviving TH positive neurons against MPTP induced toxicity
(p<0.01), without altering baseline levels of dopaminergic cell numbers in saline treated ani-
mals (p = 0.2816 Fig 1B and 1D). Furthermore, the number of DA neurons in animals receiv-
ing activin A and MPTP was not statistically different from those receiving activin A and
saline (p = 0.2434), suggesting a potent neuroprotective effect of activin A.
Activin A increases survival of nigral neuron populations following MPTP
It has been demonstrated that expression of TH may decrease during times of cell stress that
occurs during pathological events induced by Parkinsonian toxins such as MPTP [19–21]. It is
therefore necessary to control for the loss of this phenotypic marker in the absence of cell
death. To ensure that the neuroprotective effect of activin A in dopaminergic neurons against
MPTP-induced degeneration was not simply a result of decreased TH expression in vehicle
Activin A in MPTP and LPS Models
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Fig 1. Activin A protects nigral neurons against MPTP-induced cell death. (A) Experimental timeline. (B) Representative images of TH-
immunoreactive neurons in the substantia nigra pars compacta (SNpc). (C) Representative images of NeuN-immunoreactive neurons in the
SNpc. (D) Stereological quantification of TH-immunoreactive neurons in SNpc demonstrates activin A protects dopaminergic neurons against
MPTP toxicity. (E) Stereological quantification of NeuN-immunoreactive neurons in the SNpc demonstrates activin A protects total neuron
numbers against MPTP induced toxicity. All values represent the mean ± SEM. *p<0.05, **p<0.01, ***p<0.001. Scale bar represents 200μm.
N = 5/group.
doi:10.1371/journal.pone.0167211.g001
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treated animals, we also quantified the number of NeuN positive cells in the SNpc. Two-way
ANOVA revealed a significant interaction between toxin and drug treatment (F(1,16) = 15.21
p<0.01, n = 5/group), suggesting an effect of activin A on MPTP-induced cell loss. Therefore
separate t-tests of toxin and drug treatment were conducted. Administration of MPTP signifi-
cantly decreased the number of positively stained NeuN cells in animals receiving vehicle
(t = 12.48, df = 8, p<0.0001 Fig 1C and 1D), however activin A significantly protected against
this loss (t = 4.656, df = 8, p<0.01) without altering the baseline number of NeuN positive cells
in saline treated animals (t = 0.1176, df = 8, p = 0.9093). Furthermore the number of NeuN
positive cells did not differ in animals receiving activin A and lesioned with MPTP, compared
to their saline controls (t = 0.6578, df = 8, p = 0.5291, Fig 1C and 1E). Combined, these results
indicate a complete protection of total neuron numbers with activin A.
Activin A does not alter striatal dopamine levels following MPTP
The loss of dopaminergic neurons within the SN in PD results in a subsequent loss of DA in
the striatum. As we demonstrated that activin A treatment is able to protect against both dopa-
minergic and total neuron loss induced by MPTP toxicity, we hypothesized that activin A
treatment would also result in a concurrent protection of striatal DA levels. We therefore
quantified catecholamine levels from striatal tissue and analyses for DA, DOPA, HVA, and
NE via HPLC coupled to an electrochemical detector was conducted.
It has been well documented that MPTP-induced toxicity results in a significant decrease in
striatal DA levels, an effect that we have replicated here (Fig 2A; F(1,18) = 210.9 p<0.001, n =
5-7/group) with animals receiving PBS (p<0.001) and activin A (p<0.001) both displaying sig-
nificant loss of striatal DA following MPTP. However, two-way ANOVA did not reveal any
significant main effect of drug treatment on DA levels (F(1,18) = 0.145 p = 0.7078) with no sig-
nificant difference found in DA levels between MPTP treated animals receiving PBS and those
receiving activin A (p>0.9999), suggesting that activin A does not protect against loss of DA
levels following MPTP. Furthermore, this was not due to insufficient levels of activin A as
ELISA analysis demonstrated that i.c.v delivery of activin A resulted in significant quantities of
activin A in both the midbrain and striatum (S1 Fig).
Following its release from presynaptic terminals, DA either binds to and activates the DA
receptors D1 to D5 [22], or is actively translocated from the extracellular space into presynap-
tic neurons and surrounding glial cells via the dopamine transporter where it is then either
repackaged into synaptic vesicles or degraded into its metabolites DOPAC and HVA [23]. We
therefore quantified the amount of these metabolites within the striatum in order to investigate
if they were altered with the administration of activin A. Two-way ANOVA with post hoc Bon-
ferroni corrections revealed no significant effect of activin A on baseline DOPAC (p = 0.2466)
or HVA (p = 0.1877) levels (Fig 2B and 2C). While the administration of MPTP significantly
decreased DOPAC levels (Fig 2B), there was no significant difference between MPTP-treated
animals receiving PBS or activin A (p>0.9999). Similarly, MPTP administration resulted in a
significant reduction in HVA levels (Fig 2C), however no significant difference was found
between PBS and activin A groups treated with MPTP (p<0.9999). Furthermore, activin A
does not alter the catabolism of DA to HVA, with two-way ANOVA analysis revealing no sig-
nificant difference in the ratio of these two catecholamines between animals receiving PBS or
activin A, treated with MPTP (Fig 2D p = 0.7630).
Activin A increases striatal norepinephrine levels
Following conversion of DOPA to DA by DOPA decarboxylase, DA is transported into vesicles
where it can also be converted to NE by dopamine β-hydroxylase. While not as extensively
Activin A in MPTP and LPS Models
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studied as DA, evidence suggests that NE may play a role in the degenerative process of PD
[24,25]. We therefore also examined the levels of NE in the striatum following MPTP. Interest-
ingly, two-way ANOVA revealed no significant effect of MPTP treatment on NE levels (F(1,18) =
0.001491 p = 0.9696, n = 5-7/group), however a significant drug effect was found (F(1,18) = 23.91
p<0.0001) suggesting a potential role of activin A on NE levels. Post hoc analysis with Bonfer-
roni corrections demonstrated that activin A significantly increased levels of NE both in saline
(p<0.05) and MPTP (p<0.001) treated groups (Fig 2E). However MPTP did not alter this
increase in NE levels, with no significant difference between animals receiving activin A and
treated with saline, and animals receiving activin A and treated with MPTP (p>0.9999).
Tyrosine hydroxylase phosphorylation is altered by activin A following
MPTP
Tyrosine hydroxylase can be regulated by phosphorylation at multiple serine residues, includ-
ing serine 19, 31 and 40 by various kinases, resulting in increased stability and/or activity of
the enzyme and subsequent increases in DA levels [26]. Our previous results demonstrated
that while activin A is able to protect the DA producing cell bodies in the SN, there is no subse-
quent protection of DA levels in the striatum. To investigate if this failure to increase striatal
DA levels resulted from alterations to tyrosine hydroxylase activity, we analyzed expression of
ser40 and ser31 phosphorylated TH via immunoblotting.
Fig 2. Activin A does not alter striatal dopamine levels following MPTP. HPLC-ECD quantification of
catecholamine levels revealed that activin A does not alter striatal DA (A), DOPAC (B), or HVA (C) levels
following MPTP administration. Activin A did not alter the catabolism of DA to HVA (D) following MPTP
administration. Activin A significantly increased striatal NE levels (E). All values represent the mean ± SEM.
*p<0.05, ***p<0.001. N = 5-7/group.
doi:10.1371/journal.pone.0167211.g002
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Two-way ANOVA analysis revealed a significant overall effect of MPTP on both striatal
p-TH(ser40) (F(1,20) = 10.41 p<0.01, n = 6/group), and p-TH(ser31) expression (F(1,20) = 21.74
p<0.001, n = 6/group). However no overall effect of drug treatment on either p-TH(ser40)
(F(1,20) = 0.2132 p = 0.6493) or p-TH(ser31) expression in the striatum (F(1,20) = 1.745 p =
0.2014) was found. Post hoc analysis revealed no significant difference in serine phosphoryla-
tion in saline treated animals receiving either PBS or activin A (p>0.9999), indicating that acti-
vin A does not alter baseline levels of p-TH(ser40) or p-TH(ser31) expression (Fig 3A–3D).
However, animals receiving activin A and MPTP displayed a significant increase in p-TH
(ser40) expression compared to their saline treated controls (p<0.05 Fig 3B). In contrast,
while MPTP did not alter p-TH(ser31) expression in animals receiving PBS (p = 0.0642), acti-
vin A significantly lowered expression levels compared to saline treated controls (p<0.001
Fig 3D). Together, these results indicate that activin A alters MPTP-induced changes in TH
phosphorylation.
Fig 3. Activin A alters TH phosphorylation but not striatal DAT following MPTP. Western blot analysis of
striatal protein extracts from animals receiving PBS or activin A 8 days after MPTP. Representative bands of
TH, GAPDH and (A) p-TH(ser40) and (C) p-TH(ser31) expression. Quantification of p-TH(ser40)/TH (B) and
p-TH(ser31)/TH (D) protein expression normalized to GAPDH (n = 6/group). (E) Representative bands of
DAT and GAPDH expression. (F) Quantification of DAT protein expression normalized to GAPDH. All values
represent the mean ± SEM. *p<0.05, ***p<0.001. N = 6-7/group.
doi:10.1371/journal.pone.0167211.g003
Activin A in MPTP and LPS Models
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Activin A does not protect striatal terminals against MPTP-induced
degeneration
In the striatum, the DAT plays an important role for maintaining sufficient DA levels for
release into the synaptic cleft, thus when striatal DAT loss reaches levels equivalent to those
seen upon presentation of locomotor symptoms, a concomitant deficit in DA is produced [27–
29]. To investigate if the inability of activin A to restore DA levels in the striatum following
MPTP was due to a deficit in DAT, we quantified striatal DAT levels via immunoblotting.
Two-way ANOVA analysis, revealed no significant overall effect of MPTP (F(1,21) = 3.999
p = 0.0586, n = 6-7/group), and no significant overall effect of drug treatment (F(1,21) = 0.04795
p = 0.8288) on DAT expression. Furthermore, no significant difference was found in saline
treated animals receiving either PBS or activin A (p>0.9999), indicating that activin A does
not alter baseline levels of DAT expression (Fig 3E and 3F). These results suggest that unlike
the neuroprotective effect seen in the SN, activin A does not protect the dopaminergic fibers in
the striatum.
Activin A protects dopamine neuron numbers 8 weeks following MPTP
Much like that seen in the early phases of human PD in which the dopaminergic system is able
to compensate for the initial degeneration, numerous studies have demonstrated that sponta-
neous recovery is able to occur in rodents that have been rendered parkinsonian by MPTP
[30–32]. To investigate if our effects of activin A are due to any potential neuroprotective prop-
erties or simply a result of spontaneous recovery in these animals, a second cohort of mice was
quantified for TH positive cells in the SNpc 8 weeks after MPTP administration.
Two-way ANOVA revealed a significant interaction between toxin and drug treatment
(F(1,17) = 5.594 p<0.05, n = 5-6/group) suggesting a potential effect of activin A on the long-
term toxicity of MPTP. Therefore, separate t-tests were conducted on toxin and drug treat-
ment. As expected, activin A did not alter baseline levels of dopaminergic cells (t = 0.1115,
df = 8, p = 0.9140), while MPTP significantly decreased the number of TH positive cells in ani-
mals receiving PBS (t = 4.747, df = 9, p<0.01 Fig 4B). Interestingly activin A significantly
increased the number of surviving TH positive cells following MPTP (t = 3.000, df = 9 p<0.05)
to a level that was not significantly different from their saline controls (t = 0.7139, df = 8,
p = 0.4956) suggesting that short term administration of activin A is able to protect dopamine
neurons up to 8 weeks following MPTP (Fig 4B).
Activin A protects total neuron numbers 8 weeks following MPTP
We also examined the effect of activin A on total neuron numbers 8 weeks after MPTP admin-
istration by quantifying the number of NeuN positive cells within the SNpc. Two-way
ANOVA revealed a significant interaction between toxin and drug treatment (F(1,16) = 17.76
p<0.001, n = 5/group) suggesting a potential effect of activin A on the long-term survival of
nigral neurons following MPTP. Therefore, separate t-tests were conducted on toxin and drug
treatment. We demonstrated that, much like the results seen with TH, activin A did not alter
baseline levels of neuron numbers at 8 weeks post MPTP (t = 0.2298, df = 8, p = 0.8240 Fig
4C). While MPTP significantly decreased the number of NeuN positive cells in animals receiv-
ing PBS (t = 8.720, df = 8, p<0.001), activin A significantly increased the survival of NeuN pos-
itive cells compared to controls (t = 7.127, df = 8, p<0.001 Fig 4C). Furthermore, there was no
significant difference in NeuN positive cells in MPTP-treated animals receiving activin A
compared to their saline controls (t = 0.9319, df = 8, p = 0.3786) indicating that short term
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Fig 4. Activin A protects midbrain neurons up to 8 weeks post-MPTP. Stereological quantification
demonstrates activin A protects SNpc dopaminergic neurons (A) and total neuron numbers (B) against long-
term MPTP induced toxicity. No significant effect of activin A on striatal DA (C), DOPAC (D) or HVA levels (E)
the turnover of DA to HVA (F) or striatal NE levels (G) was found 8 weeks post-MPTP. (H) Representative
images of DAT and GAPDH expression. (I) Western blot analysis of striatal protein extracts revealed activin A
does not protect DAT expression 8 weeks post-MPTP. All values represent the mean ± SEM. *p<0.05
**p<0.01, ***p<0.001. N = 3-13/group.
doi:10.1371/journal.pone.0167211.g004
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administration of activin A is able to completely protect against MPTP-induced cell death up
to 8 weeks after lesioning.
Activin A does not alter striatal dopamine content 8 weeks following
MPTP
To investigate if activin A alters striatal DA content past the initial degeneration phase, we ana-
lyzed the levels of striatal DA, DOPAC, and HVA 8 weeks after the last injection of MPTP.
Two-way ANOVA analysis demonstrated a significant overall effect of MPTP on both DA
(F(1,13) = 4.732 p<0.05, n = 3-5/group) and DOPAC (F(1,13) = 6.246 p<0.05, n = 3-5/group) lev-
els, while no significant overall effect of MPTP was found on HVA levels (F(1,13) = 1.535
p = 0.2373, n = 3-5/group). Furthermore, no significant overall effect of drug treatment on DA
(F(1,13) = 0.3358 p = 0.5722), DOPAC (F(1,13) = 0.02681 p = 0.8725) or HVA (F(1,13) = 0.7387
p = 0.4056) was found. However, post hoc analysis revealed no significant difference in DA or
DOPAC levels between animals receiving PBS and activin A in both saline and MPTP-treated
groups (Fig 4D–4F).
Interestingly, two-way ANOVA revealed a significant interaction between toxin and drug
treatment in the ratio of DA to HVA (F(1,13) = 5.323 p<0.05, n = 3-5/group) suggesting a
potential effect of activin A on the catabolism of DA following MPTP. Therefore t-tests of
toxin and drug were performed and it was found MPTP-treated animals receiving PBS dis-
played a significantly greater turnover of DA to HVA compared to their saline controls (Fig
4G t = 4.940, df = 7, p<0.01). However, no difference in the ratio of DA to HVA between
MPTP-treated animals receiving either PBS or activin A was found (t = 2.453, df = 5,
p = 0.0578).
We also investigated if activin A was able to maintain its increase in striatal NE levels at 8
weeks after the administration of MPTP. As expected, two-way ANOVA demonstrated no sig-
nificant overall effect of MPTP (F(1,13) = 0.7078 p = 0.4154, n = 3-5/group) on striatal NE levels.
However in contrast to our previous results we found no significant overall effect of drug treat-
ment (F(1,13) = 0.3297 p = 0.5756), suggesting activin A does not increase NE levels in the stria-
tum 8 weeks after lesioning with MPTP (Fig 4H).
Activin A does not protect dopamine transporter levels 8 weeks after
MPTP
To further investigate the potential long term effects of activin A, we quantified DAT
expression in the striatum 8 weeks after MPTP administration. While two-way ANOVA
revealed a significant overall effect of MPTP on DAT expression (F(1,42) = 26.80 p<0.001,
n = 10-13/group), no significant effect of activin A was found (F(1,42) = 0.08766 p = 0.7686).
Post hoc analysis demonstrated that MPTP resulted in a significant decrease in DAT levels
in animals receiving PBS (p<0.001), indicating that degeneration in the striatum is main-
tained up to 8 weeks (Fig 4I and 4J). However, while activin A administration did not alter
baseline levels of DAT expression (p>0.9999), animals receiving activin A had significantly
decreased DAT expression following MPTP lesioning at 8 weeks compared to saline con-
trols (p<0.01) suggesting that activin A is unable to prevent long-term degeneration in the
striatum following MPTP.
Activin A decreases astrocyte and microglial numbers following MPTP
Numerous studies have shown that in addition to its selective degeneration of the dopaminer-
gic system, the MPTP model of PD results in a significant increase in inflammatory cells in the
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SNpc [7,33–35]. It has been previously demonstrated that activin A administration results in a
decrease in the total number of astrocytes and microglia in the hippocampus following an exci-
totoxic injury, thus demonstrating a potential anti-inflammatory effect of activin A [16]. We
therefore investigated if activin A displayed similar anti-inflammatory properties following
MPTP administration by quantifying the number of astrocytes and microglia via stereological
analysis of GFAP and Iba1 immunoreactive cells, respectively, in the SNpc. Two-way ANOVA
demonstrated a significant overall effect of MPTP on both GFAP (F(1,10) = 19.41 p<0.01,
n = 3-4/group) and Iba1 (F(1,11) = 41.36 p<0.001, n = 3-4/group) cell numbers in the SNpc.
Interestingly, there was no significant overall effect of drug treatment on GFAP positive cells
(F(1,10) = 4.484 p = 0.0603), however, a significant overall effect of drug treatment on Iba1 posi-
tive cells (F(1,11) = 6.232 p<0.05) was found.
Post hoc analysis demonstrated no significant difference in GFAP positive cells between
animals receiving PBS or activin A in the saline treated groups (p>0.9999), indicating that
activin A does not alter the baseline level of astrocyte populations (Fig 5A). As expected,
MPTP administration significantly increased GFAP positive cells in animals receiving PBS,
compared to saline controls (p<0.01) indicating that MPTP was able to induce an inflamma-
tory response (Fig 5A). We also found that activin A significantly lowered the number of
GFAP positive cells following MPTP administration compared to controls (p<0.05) to levels
that were not statistically significant different compared to animals receiving activin A and
saline (p = 0.1332) suggesting that activin A was able to completely dampen the MPTP-
induced astrocytic response.
Similarly, no significant difference in Iba1 positive cells was found between animals receiv-
ing PBS or activin A in the saline treated groups (p>0.9999), indicating that activin A does not
alter the baseline level of microglial populations. As expected, MPTP significantly increased
Iba1 positive cells in animals receiving PBS, compared to saline controls (p<0.001 Fig 5B).
However, MPTP administration also increased the number of Iba1 positive cells in animals
receiving activin A (p<0.05). Regardless, the increase in Iba1 positive cells was smaller in ani-
mals receiving activin A (Fig 5B), with a significant difference between animals receiving PBS
and activin A in the MPTP treated groups (p<0.05). Together, these results indicate a potential
anti-inflammatory effect of activin A, with the growth factor able to reduce both astrocyte and
microglia populations following MPTP.
Activin A decreases LPS-induced inflammation
LPS is a well-known potent inducer of inflammation, resulting in the production of pro-
inflammatory cytokines and the subsequent activation of both astrocytes and microglia. To
investigate if activin A is neuroprotective against a direct inflammatory mechanism we admin-
istered LPS (or vehicle PBS) directly into the SN, with or without activin A, and quantified the
remaining number of astrocytes and microglial numbers via stereology (Fig 5C).
As expected, one-way ANOVA demonstrated a significant difference of both GFAP
(F(2,10) = 16.51, df = 2, p<0.001, n = 4-5/group) and Iba1 (F(2,12) = 8.348 p<0.01, n = 4-5/group)
positive cells numbers in the SNpc between treatment groups. Post hoc analysis revealed a sig-
nificant difference between animals injected with PBS and animals injected with LPS alone for
both GFAP (p<0.001) and Iba1 positive cells (p<0.01), indicating that LPS is able to induce a
significant inflammatory response in the SNpc (Fig 5D and 5E). Furthermore, animals treated
with activin A displayed fewer GFAP (p<0.5) and Iba1 (p<0.05) positive cells compared to ani-
mals injected with LPS alone. Interestingly, there was no significant difference in either GFAP
positive cells (p = 0.1854) or Iba1 positive cells (p = 0.8269) between animals receiving activin A
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Fig 5. Activin A decreases MPTP and LPS-induced inflammation. Stereological quantification of the left
SNpc demonstrated activin A significantly decreased the number of GFAP-immunoreactive cells (A) and
Iba1-immunoreactive cells (B) in the SNpc following MPTP. (C) Timeline detailing LPS experimental
procedures. Stereological quantification demonstrated activin A significantly reduces the LPS-induced
increase in GFAP (D) and Iba1 (E) positive cells and subsequent loss of TH (F) and NeuN (G) positive cells.
(H) Representative images of DAT and GAPDH expression. (I) Western blot analysis of striatal protein
extracts revealed LPS does not alter DAT expression. All values represent the mean ± SEM. *p<0.05,
**p<0.01, ***p<0.001. N = 3-5/group.
doi:10.1371/journal.pone.0167211.g005
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and those injected with PBS. Together, these results demonstrate that activin A administration
significantly decreases LPS-induced increases in inflammatory cell populations in the SNpc.
Activin A protects against LPS-induced cell death in the SNpc
To investigate if LPS-induced inflammation results in cell death in the SNpc and if activin A is
able to protect against this degeneration, we quantified the number of TH and NeuN positive
cells via stereology. One-way ANOVA demonstrated a significant difference of both TH posi-
tive (F(2,12) = 15.02 p<0.001, n = 5/group) and NeuN positive (F(2,12) = 12.26 p<0.01, n =
5/group) cell numbers in the SNpc between treatment groups. Post hoc analysis revealed a sig-
nificant difference between animals injected with PBS and animals injected with LPS alone for
both TH (Fig 5F; p<0.001) and NeuN positive cells (Fig 5G; p<0.01). However SN injection of
LPS was unable to induce changes to DAT expression across all treatment groups (F(2,12) =
0.3326, p = 0.7303), indicating that LPS is able to induce cell death in the SNpc but not degen-
eration in the striatum (Fig 5H and 5I). Furthermore animals treated with activin A displayed
more TH positive (p<0.01) and NeuN positive (p<0.05) cells in the SNpc compared to animals
injected with LPS alone. Most excitingly, there was no significant difference in either TH posi-
tive cells (p = 0.8708) or NeuN positive cells (p = 0.4610) between animals receiving activin A
and those injected with PBS (Fig 5F–5G). Together, these results demonstrate that activin A is
able to completely protect against cell death in the SN via an anti-inflammatory mechanism.
Discussion
The use of growth factors has received intense focus in recent years as a potential therapy to
halt or even reverse the progressive DA neuronal death in PD, based on their ability to pro-
mote induction, specification, survival and maturation of developing neurons within the CNS.
Following promising neuroprotective and neurorestorative results in animal models, clinical
trials of the growth factors GDNF and Neurturin in PD patients were conducted. However,
the results of these clinical trials proved largely disappointing, with some endpoints not met,
site delivery and retrograde transport issues, and the presence of unwanted lesions dampening
results [36–40]. Despite these translational issues, optimism remains that growth factors, and
in particular those of the TGF-β superfamily, will prove useful as a therapeutic intervention for
PD. However, the mechanisms by which these growth factors ameliorate PD pathology still
remain to be fully understood.
While the neuroprotective potential of activin A has been demonstrated previously in the
hippocampus following acute brain injury [3], the first evidence that activin A may also exert
neuroprotective effects in PD-related CNS regions was revealed when administration of the
growth factor significantly attenuated degeneration induced by 6-OHDA [5] and MPP+ [4] in
vitro. This study is the first to demonstrate that the anti-inflammatory role of activin A may
contribute to its neuroprotective effects in an in vivo model of PD.
The MPTP model of PD remains the most widely used model to study potential neuropro-
tective therapeutic targets as it replicates the selective death of dopaminergic neurons within
the SN. It has been previously reported that an acute regimen of MPTP results in a loss of
dopaminergic cell bodies in the SN that is stable by 7 days after MPTP administration [41].
Following infusion of activin A (or vehicle) for 1 week stereological analysis revealed that
administration of activin A for 7 days resulted in a significant protection of both dopaminergic
and total neuron populations in the SNpc against MPTP-induced toxicity, suggesting that
administration of activin A throughout the entire period of MPTP toxicity offers profound
neuroprotection within the SN. It would be interesting for future translational studies to
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determine if these surviving neurons exhibited the same electrophysiological properties as
those found in unlesioned animals.
The loss of DA producing cells within the SN of PD patients results in a subsequent loss of
DA within the striatum, and ultimately a disruption of the finely tuned signaling of the BG. As
we demonstrated that activin A resulted in significant protection of dopaminergic and total
neuron populations in the SN, we hypothesized that exogenous activin A would also result in a
subsequent protection of DA levels. However, activin A treatment was unable to attenuate this
loss of DA levels, or its metabolites DOPAC and HVA. Furthermore this was not due to activin
A altering the catabolism of DA, with no difference in the ratio of DA to HVA found between
animals receiving vehicle or activin A. These results suggest that while activin A protects
against MPTP-induced degeneration of nigral cell bodies, this neuroprotection does not trans-
late to a subsequent protection of DA levels in the striatum. Interestingly, this finding repli-
cates a previous study in which cyclooxygenase-2 (COX-2) deficient mice exhibited reduced
dopaminergic cell loss following MPTP, but maintained a deficit of approximately 70% striatal
DA levels [42].
Standard MPTP dosing regimes, including the acute MPTP protocol used in this study,
result in profound striatal DA depletion with little to no evidence of alterations of NE content
in mice [43–45]. It is therefore interesting to note that exogenous activin A significantly
increases levels of striatal NE in both saline and MPTP injected animals. In nerve terminals
containing dopamine-β-hydroxylase, NE is formed in the next step in the catecholamine syn-
thesis pathway beyond DA production, and has been demonstrated to be greatly reduced in
several brain regions in PD patients [46]. Furthermore, it has been suggested that activation of
α2 adrenergic receptors, thus decreasing NE neurotransmission, can facilitate movements pro-
duced by the activation of the direct pathway of the basal ganglia, thus highlighting enhanced
α2 receptor stimulation as a potential mechanism underlying L-dopa-induced dyskinesias
[47]. Indeed, α2 adrenergic antagonists have been shown to reduce L-dopa-induced motor
effects in 6-OHDA lesioned rodents [48,49]. Therefore the role of activin A in NE transmis-
sion, and subsequent effect on motor function would warrant further investigations.
The production of DA within the CNS is a two-step biosynthesis that takes place within the
cytosol of catecholaminergic neurons, beginning with the hydroxylation of L-tyrosine by TH
to yield DOPA [50]. TH activation by phosphorylation is the primary mechanism responsible
for the maintenance of catecholamine levels after catecholamine secretion in tissues and occurs
at serine 19, 31 and 40 by various kinases to increase stability and/or activity of TH [26,50]. To
investigate if the failure of activin A to restore striatal DA levels resulted from alterations to
DA synthesis, we quantified changes in striatal expression of phosphorylation at the two major
sites responsible for TH activity, ser40 and ser31. We found that following MPTP administra-
tion, there was a significant increase in phosphorylation at ser40 and a concomitant decrease
at ser31 in animals that were infused with activin A. These results suggest that in the presence
of nigrostriatal degeneration and DA loss, a compensatory mechanism involving activin A to
increase the phosphorylation of TH at ser40, the most important site in the regulation of TH
activity, occurs in an attempt to stimulate DA production and replenish the DA that is lost.
However, despite this increase in phosphorylation at ser40, this does not result in an increase
in striatal DA levels, suggesting that activin A may (1) alter the DA production pathway further
downstream or (2) inhibit the activity of protein phosphatase 2A (PP2A), thus inhibiting the
dephosphorylation of TH at ser40. Further experiments investigating the effects of activin A
on other important regulators of DA biosynthesis such as aromatic amino acid decarboxylase
(AADC), as well as its potential to inhibit PP2A would be required to understand activin A’s
role in regulating DA levels in the striatum more fully.
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In the striatum, the dopamine transporter plays an important role for maintaining suffi-
cient DA levels for release into the synaptic cleft and is the primary determinant of the lifetime
of extracellular DA, thus when striatal DAT loss reaches levels equivalent to those seen upon
presentation of locomotor symptoms, a concomitant deficit in DA is produced [27–29]. It is
therefore possible that the decrease in striatal DA levels in animals receiving activin A, despite
the increase in survival of DA producing cells and an increase in TH phosphorylation, is due
to the degeneration of the DAT in the projecting fibers from the nigral cell bodies. Quantifica-
tion of DAT expression in striatal protein homogenates demonstrated no changes between
vehicle and activin A treated animals following MPTP. While it could be suggested this may be
due to an inability of i.c.v infusion to allow for insufficient levels of activin to reach the striatal
region, our quantification of activin A in this region demonstrates this is not a factor. However
despite a trend towards loss of DAT expression 1 week after MPTP, this effect was not signifi-
cant in either treatment group, suggesting that this timeframe was insufficient for loss of stria-
tal integrity.
There is substantial evidence that spontaneous recovery is able to occur in rodents that
have been rendered parkinsonian by MPTP, similar to the compensatory effects that occur in
the early stages of PD [51]. We therefore investigated if the neuroprotective effects of activin A
extended past the initial degenerative phase by examining levels of nigrostriatal protection 8
weeks after the administration of MPTP. We found that activin A treatment was able to main-
tain protection of both dopaminergic and total neuronal populations in the SNpc in the long-
term, even in the absence of continued activin A infusion. This result is similar to that seen
with previous studies, in which short-term infusion of activin A regulated neurogenesis in the
hippocampus up to 5 weeks later [16]. However, much like that seen in the earlier experiments
of this study, activin A was not able to subsequently restore levels of striatal DA, or its metabo-
lites DOPAC and HVA. A study conducted by Jones et al., (1998) suggests that the mainte-
nance of normal stores of DA are dependent on recycled rather than newly synthesized DA
[29], therefore the loss of striatal DAT expression in activin A treated animals 8 weeks after
MPTP, allowing for limited extracellular DA to be taken up into presynaptic terminals rather
than be degraded, may not be enough to maintain striatal DA levels. In contrast to our previ-
ous results, NE levels were unchanged in activin A infused animals, demonstrating that the
increase in NE levels seen 8 days after MPTP administration is not maintained long term. This
suggests that activin A may need to be constantly administrated to the brain to maintain con-
sistent levels of NE in the striatum.
Our findings here, showing a neuroprotective effect that appears to be localized to the SN,
reflects a similar outcome to that of a recently published study in which activin A significantly
protected nigral neurons but not striatal DA and DAT levels against 6-OHDA-induced toxicity
in vivo [6]. Combined, this raises a number of interesting points. It is possible that proximity
of administration of activin A to the site of degeneration is required for any neuroprotective
effects to occur in the striatum, much like that seen with GDNF and Neurturin in animal mod-
els of PD [52–57]. While our method of i.c.v infusion resulted in diffusion to the striatum, it
may be that there is still insufficient activin A levels to inhibit striatal loss. However, it is
unknown, at least in the MPTP model where degeneration is not localized to one area, if any
neuroprotection as a result of administration of activin A in the striatal region would come at
a consequence of neuroprotection in the SN.
While it has long been known that growth factors support and promote the survival of
midbrain neurons in animal models of PD, the exact mechanisms of this protection remains
to be fully elucidated. It has previously been demonstrated that i.c.v administration of activin
A exerts profound anti-inflammatory effects in the hippocampus following an acute excito-
toxic injury through decreased total astrocyte and microglial numbers and inhibition of pro-
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inflammatory cytokine release [16], suggesting a potential mechanism for its neuroprotective
effects. Systemic injections of MPTP result in rapid astroglia and microglia-mediated
responses such as increases in cell numbers and changes in morphology, including larger cell
bodies and thickening of processes [58,59], making this model ideal to investigate activin A-
mediated inflammatory changes. Indeed, activin A suppressed the MPTP-induced inflamma-
tory response, with stereological quantification demonstrating significantly fewer number of
astrocytes and microglial cells in the SNpc in activin A infused animals. Given that previous
studies have shown that in response to the neurotoxic damage induced by MPTP in mice, neu-
rotrophic factors such as GDNF are upregulated by glia to serve a neuroprotective function
[60,61], it is therefore not unexpected that the neuroprotective and anti-inflammatory action
of activin A may linked.
However, while showing a significant reduction in inflammatory cell populations, these
results do not demonstrate that activin A’s neuroprotective effects against MPTP-induced tox-
icity are directly due to its anti-inflammatory properties. We therefore investigated the poten-
tial of activin A to inhibit a direct stimulation of inflammation by injection of LPS into the
substantia nigra, which has been previously demonstrated to result in significant degeneration
of dopaminergic neurons [62]. When administered after the inflammatory process had already
begun, activin A significantly decreased the number of astrocytes and microglia 2 weeks after
the injection of LPS. These results confirm previous studies in which activin A inhibits the
function of LPS-activated macrophages in vitro and in vivo [63–65]. Furthermore, while LPS
resulted in a significant degeneration within the SN but not in the striatum, activin A adminis-
tration resulted in the complete protection of dopaminergic and total neuron populations. A
study conducted by Li et al (2013) showed that activin A inhibited LPS-induced changes via
down-regulating TLR4 not TLR2 [66], suggesting a potential avenue for exploring the mecha-
nisms underlying activin A-mediated inflammation. These results indicate that much like its
effects in the hippocampus, activin A is a potent anti-inflammatory agent in the midbrain, a
region with the highest density of microglia [67], and it is this anti-inflammatory property that
contributes to its neuroprotective effects, a previously unknown action of activin A. Investiga-
tions into the effect of activin A on other regulators of inflammation following MPTP toxicity
such as cytokine release, nitric oxide levels, and quantification of activated glial cells via mor-
phology changes will further consolidate this relationship.
Conclusions
Despite decades of research, L-Dopa remains the single most effective treatment for PD, how-
ever this treatment strategy comes with its own set of drawbacks and furthermore does not
address the underlying degeneration that is characteristic of the disease. Growth factors have
demonstrated significant neuroprotective effects in multiple animal models of PD, however
the mechanism by which they provide these effects has yet to be fully understood. The findings
presented in this study provide the first evidence that exogenous activin A is able to signifi-
cantly increase the survival of midbrain dopaminergic and total neuron populations through a
potential anti-inflammatory mechanism.
Supporting Information
S1 Fig. Activin A levels in the midbrain and striatum. ELISA analysis demonstrates that i.c.v
administration of activin A significantly increased levels of activin A in both the midbrain (A)
and striatum (B) when analysed 24 hours after lesioning with MPTP. All values represent the
mean ± SEM. p<0.001. N = 9-13/group.
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